Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Emanuele D’Amico, Clara G Chisari, Lara Gitto, Aurora Zanghì, Simona Toscano & Francesco Patti. (2019) Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy 20:11, pages 1331-1340.
Read now
Read now
Saeed Taheri, Mohammad Ali Sahraian & Nazila Yousefi. (2019) Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. Journal of Medical Economics 22:1, pages 71-84.
Read now
Read now
Hongbo Yang, Emilie Duchesneau, Rebekah Foster, Annie Guerin, Esprit Ma & Nina P. Thomas. (2017) Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Journal of Medical Economics 20:10, pages 1056-1065.
Read now
Read now
Articles from other publishers (13)
Ricardo Ginestal, Carlos Rubio-Terrés, Olga Durán Morán, Darío Rubio-Rodríguez, Heidi De Los Santos, Cristina Ordoñez & Isabel Sánchez-Magro. (2023) Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain. Journal of Comparative Effectiveness Research 12:2.
Crossref
Crossref
Y. Seitaridou, M. Dimitrova, T. Chamova, M. Kamusheva & P. Panayotov. (2022) Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review. Acta Medica Bulgarica 49:4, pages 69-80.
Crossref
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
S. Simeonova & R. Nikolova. (2021) Significance of the Dominant Psychological and Physiological Aspects of the Occupational Stress Models. Acta Medica Bulgarica 48:4, pages 33-42.
Crossref
Crossref
Ravirajsinh N. Jadeja, Folami L. Powell & Pamela M. Martin. 2020. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications.
Ingrid E. H. Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels & Nick Bansback. (2020) Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical Decision Making 40:8, pages 1003-1019.
Crossref
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Crossref
Lisa Batcheller & David Baker. (2019) Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences 404, pages 19-28.
Crossref
Crossref
Sen Lin. 2019. The Science and Regulations of Naturally Derived Complex Drugs. The Science and Regulations of Naturally Derived Complex Drugs
271
295
.
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref
Sergio Iannazzo, Ange-Christelle Iliza & Louise Perrault. (2017) Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36:2, pages 189-204.
Crossref
Crossref
Camille B. Carroll & Richard K.H. Wyse. (2017) Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress. Journal of Parkinson's Disease 7:4, pages 545-568.
Crossref
Crossref
Andrew Chan, Gary Cutter, Robert J Fox, James Xiao, James B Lewin & Michael R Edwards. (2017) Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research 6:4, pages 313-323.
Crossref
Crossref